CD19 and B-cell acute lymphoblastic leukemia: In hematological malignancies, CAR-T cells have set a high benchmark, with CD19-directed products achieving complete response rates of 70%–90% in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma [2, 8].